Conditions: Non-Small Cell Lung Cancer Lung Cancer, Non-Small Cell
Keywords: pazopanib I-ELCAP non-small cell lung cancer antiangiogenesis NSCLC GW786034
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 35
Healthy volunteers: no

Brief summary:
This is a phase 2 open-label, multicenter, non-randomized study to evaluate the safety and efficacy of oral pazopanib as neoadjuvant treatment for patients with stage 1A, 1B, IIA or IIB (to T2) resectable Non-Small Cell Lung Cancer (NSCLC).

Detailed description:

Arms:
arm 1: 800 mg pazopanib oral daily

Interventions: intervention 1: Pazopanib
Intervention descriptions: intervention 1: Pazopanib is an oral, potent, multi-target receptor tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit. Subjects were to receive 800 mg oral pazopanib daily for a minimum of 2 weeks to a maximum of 6 weeks.

Protocol document: